We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii
Product News

DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii

DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii
Product News

DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DiaSorin Molecular has announced the expansion of its menu of molecular reagents with the introduction of a Pneumocystis jirovecii primer pair for use in laboratory-developed molecular tests. This analyte-specific reagent (ASR) can be used for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers. This is DiaSorin’s first fungal infectious disease target. 

 
The new primer pair joins DiaSorin’s menu of more than 60 molecular reagents that can be used to detect bacterial and viral targets in addition to human genetic mutations. The primer pairs are classified as analyte-specific reagents, which are used by high-complexity laboratories to develop their own lab-developed tests (LDTs). 
 
“This new primer pair is the result of our ongoing work to develop and deliver a robust menu of molecular products,” said Michelle Tabb, vice president of research and development for DiaSorin Molecular. “With greater access to commercially developed molecular reagents, diagnostic labs are better able to customize tests that meet their unique patient needs.”

Advertisement